Get started
Author

Michael C. Sabel

Observed name: Michael Sabel
OpenAlex ID: A5071464512
Multimodal Imaging-guided Tissue Sampling Combined with Multiomics Profiling Informs on Spatial Molecular and Cellular Heterogeneity Linked to Distinct Imaging Features in Diffuse Gliomas
2026 · Niklas Tillmanns, Niklas Joern Tillmanns, et al. · Brain and Spine
PDF
Supplementary Figure 1 from MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial
2023 · Michael Weller, Ghazaleh Tabatabai, et al.
Supplementary Tables 1-7 from MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial
2023 · Michael Weller, Ghazaleh Tabatabai, et al.
Data from Prognostic Significance of Molecular Markers and Extent of Resection in Primary Glioblastoma Patients
2023 · Jörg Felsberg, Marion Rapp, et al.
Data from MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial
2023 · Michael Weller, Ghazaleh Tabatabai, et al.
Data from Prognostic Significance of Molecular Markers and Extent of Resection in Primary Glioblastoma Patients
2023 · Jörg Felsberg, Marion Rapp, et al.
Data from MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial
2023 · Michael Weller, Ghazaleh Tabatabai, et al.
Supplementary Data from Prognostic Significance of Molecular Markers and Extent of Resection in Primary Glioblastoma Patients
2023 · Jörg Felsberg, Marion Rapp, et al.
Supplementary Figure 1 from MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial
2023 · Michael Weller, Ghazaleh Tabatabai, et al.
Supplementary Data from Prognostic Significance of Molecular Markers and Extent of Resection in Primary Glioblastoma Patients
2023 · Jörg Felsberg, Marion Rapp, et al.
PDF
Supplementary Tables 1-7 from MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial
2023 · Michael Weller, Ghazaleh Tabatabai, et al.
Works count: 11
Citation count:
H-index:
I10-index:
Year
Topic
Type